Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 9/20 | 0.81 |
| ▸ | HRH1 | P35367 | 9/20 | 0.81 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.81 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talastine SCHEMBL30502 | 1.00 | ADRA1A (0.81) | ADRA1AHRH1ADRA1BHRH3TSHR | |
| Talastine SCHEMBL1650995 | 0.97 | ADRA1A (0.78) | ADRA1AHRH1ADRA1BHRH3TSHR | |
| Talastine SCHEMBL13724065 | 0.83 | HRH1 (0.58) | ADRA1AHRH1ADRA1BHRH3TSHR | |
| SCHEMBL10482471 | 0.82 | ADRA1A (0.61) | ADRA1AHRH1ADRA1BHRH3TSHR | |
| SCHEMBL16363659 | 0.82 | TSHR (0.64) | ADRA1AHRH1ADRA1BHRH3TSHR | |
| SCHEMBL12877772 | 0.81 | TSHR (0.71) | ADRA1AHRH1ADRA1BHRH3TSHR | |
| Talastine SCHEMBL28086448 | 0.80 | HRH1 (0.60) | ADRA1AHRH1ADRA1BHRH3TSHR | |
| SCHEMBL10700249 | 0.79 | ADRA1A (0.57) | ADRA1AHRH1ADRA1BHRH3TSHR | |
| SCHEMBL8556390 | 0.78 | ENPP1 (0.65) | ADRA1AHRH1ADRA1BTSHRCYP1A2 | |
| SCHEMBL12862542 | 0.78 | TSHR (0.66) | ADRA1AHRH1ADRA1BHRH3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| EP-4633602-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | Nanexa AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312275-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| EP-4536179-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | Nanexa AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| US-20250073219-A1 | NEW COMPOSITION COMPRISING IMMUNOMODULATORY DRUG | NANEXA AB (SE) | 2025-03-06 | — | — | US | disclosed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | disclosed |
| WO-2024256696-A1 | NEW INJECTABLE PHARMACEUTICAL DEPOT COMPOSITIONS | NANEXA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | disclosed |
| US-20240277749-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | NANEXA AB (SE) | 2024-08-22 | — | — | US | disclosed |
| EP-4351529-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | Nanexa AB (SE) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023237897-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| CN-111971067-B | Tannic acid-containing heart targeting agent | 韩国化学研究院 | 2023-09-08 | — | — | CN | disclosed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022258988-A1 | NEW COMPOSITION COMPRISING IMMUNOMODULATORY DRUG | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258987-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258985-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| US-11446384-B2 | Agent for targeting heart comprising tannic acid | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY | 2022-09-20 | — | — | US | disclosed |
| CN-113115799-B | Application of turmeric volatile oil | 沈阳恩柽研究院有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446384-B2 | Agent for targeting heart comprising tannic acid | TNNT2, TNNI3, TNNC1 | ADRA1A 893/4885HRH1 2274/4885ADRA1B 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.